Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Exploring inflammasome activation and targeted inhibition

NalpACT

Inflammasomes are cytosolic multi-protein complexes that form in response to a wide range of pathogens, tissue damage, and other harmful stimuli. Members of the family of NOD-like receptors (NLRs) sense these pathogen and danger associated molecular patterns, triggering innate immune responses. NLRP3 is a well-studied NLR whose activation by a...

Funding Programme
Start Date
End Date
Total Funding
€ 2 155 047
European Countries Involved

Exploring neuro-glymphatic coupling during sleep using wearable technology

GlymphoSleep

In recent years, it has been demonstrated that sleep not only plays a crucial role in cognitive, emotional, and immunological functions but also helps to clear the brain from metabolic waste products via the recently discovered glymphatic system. A physiological marker closely associated with glymphatic clearance is electroencephalographic (EEG)...

Funding Programme
Start Date
End Date
Total Funding
€ 203 464
European Countries Involved

Exposing the glial metabolism - common link to brain damage

LipidGlia

European population is rapidly aging. While it was commonly believed that brain aging leads to neuronal loss, recent studies found that instead the volume of white matter (WM) decreases and WM lesions develop with age. WM degeneration is also a hallmark of multiple neurological disorders including Alzheimers disease or multiple sclerosis...

Funding Programme
Start Date
End Date
Total Funding
€ 173 847
European Countries Involved

Fast Brillouin microscopy for phase transition

FaBriCATion

Multiple human diseases ranging from neurodegenerative disorders (such as Alzheimer´s disease) to cancer have been found to be linked with biomolecular mechanical properties change (phase transitions PTs). While these diseases have impacted many human beings (50 million for only AD), the causes of most of these diseases are still mysterious, and...

Funding Programme
Start Date
End Date
Total Funding
€ 172 750
European Countries Involved

Ferroptosis Inhibitors For Neurodegenerative Disorders

NeuroFerro

FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been...

Funding Programme
Start Date
End Date
Total Funding
€ 239 700
European Countries Involved

First Closed-loop non-Invasive Seizure Prevention System

RELIEVE

The goal of Project RELIEVE is to build the very first non-invasive effective closed-loop monitoring and intervention system for brain-related disorders. The outcomes can be used to treat or manage various psychiatric and neurological disorders. We do this by pushing the technological boundaries in two separate domains. (1) AI domain: We develop a...

Funding Programme
Start Date
End Date
Total Funding
€ 2 809 260
European Countries Involved

Fluid Biomarkers for Neurodegenerative Dementias

FLUBIODEM

Critical to our understanding of Alzheimers disease (AD) and other neurodegenerative dementias (NDDs), as well as to finding disease-modifying therapies, is the development of biomarkers for the underlying disease processes. To facilitate improved diagnostics and drug discovery, we have developed methods to measure markers of amyloid and tau...

Funding Programme
Start Date
End Date
Total Funding
€ 2 422 973
European Countries Involved

FLuorescent nanO-agents for super-Resolution Imaging and seNsing

FLORIN

Since Alzheimer disease (AD) affects up to 50% of individuals above 85, we will witness the three-fold increase in the number of patients by 2050 if no efficient therapy will be found. The FLORIN offers non-invasive real-time monitoring of key mechanisms involved in the AD pathogenesis by avant-garde bioimaging at temporal resolution less than 1...

Funding Programme
Start Date
End Date
Total Funding
€ 791 200
European Countries Involved

Focused ultrasound and microbubbles targeting alpha-synuclein pathology-related dementia (FUMA)

FUMA

Over half of Parkinson Disease patients develop cortical dysfunctions leading to Parkinson Disease Dementia (PDD). The cognitive changes are primarily driven by pathological alpha-synuclein (a-syn) protein aggregates with secondary synaptic dysfunctions in the cortex. Microglia plays a key role in synapse maintenance and clearance of aggregated a...

Funding Programme
Start Date
End Date
Total Funding
€ 230 774
European Countries Involved

Focusing on deep sleep-wake brain regions in the context of Alzheimer's disease pathogenesis: a multi-modal, high-resolution neuroimaging approach

ADEEPSLEEP

The increased prevalence of Alzheimer’s disease (AD) in our ageing society constitutes an urgent, far-reaching public health concern. In the worldwide effort to identify leverage points to prevent or delay the onset of AD, sleep has recently emerged as a potent modifiable factor to slow down the hallmark pathophysiological processes of the disease...

Funding Programme
Start Date
End Date
Total Funding
€ 272 536
European Countries Involved

Functional analysis of TSPAN14 as a genetic risk factor for Alzheimer’s disease

TSPAN14-AD

Alzheimer’s disease (AD) is the most prevalent deadly neurodegenerative disorder for which no effective treatment exists as of today. Therefore, there is an urgent need to better understand the molecular mechanisms behind AD in order to develop more effective treatments against this complex disease. Recent genetic findings have highlighted several...

Funding Programme
Start Date
End Date
Total Funding
€ 173 847
European Countries Involved

Gamma-secretase allosteric modulation as preventive therapy in Alzheimer’s Disease

GALOMOD

The recent advent of therapeutic Aβ-antibodies has validated amyloid plaques as drug targets in Alzheimer’s Disease (AD). They remain expensive, prone to side effects, and clinical benefit is limited. The field needs a safe and cheap drug, preferably a small compound that can be taken orally, and in a preventative way before brain damage has...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).